BUSINESS● LOWAug 27 · Aug 27, 2026, 12:43 PM
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Yahoo Finance
Regeneron Pharmaceuticals is adjusting its strategy following mixed results in its melanoma drug trials. This indicates a change in direction for the company's pharmaceutical development efforts.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS6m agoChina GDP growth picks up to 4.5% from 3-year lowSeeking Alpha TechBUSINESS9m agoIndonesian stocks plunge to six-year low as MSCI downgrade fears mountCNBC